POSA239 Impact of AIFA Note 96 on Vitamin D Analogs' Prescriptive Appropriateness

In October 2019, the reimbursement criteria of vitamin D(vitD) analogs for the prevention and treatment of vitD-deficiency in adults were refined by AIFA through the publication of Note-96. In the first 15 months from Note’s adoption, 30% decrease in drug-related consumptions and expenditures compared to previous periods was observed. The study aimed to verify whether this reduction was related to greater appropriateness in vitD analogs use.